

Revision date: 15-Dec-2006 Version: 1.1 Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Dextropropoxyphene Hydrochloride Capsules

Trade Name: DEPRANCOL®

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as opioid analgesic

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Dextropropoxyphene Hydrochloride	1639-60-7	216-683-5	150 mg ***
Corn Starch	9005-25-8	232-679-6	*
Talc (non-asbestiform)	14807-96-6	238-877-9	*

Ingredient	CAS Number	EU EINECS List	%
Povidone	9003-39-8	Not listed	*
Gelatin	9000-70-8	232-554-6	*
FD & C Red No. 3 (E 127)	16423-68-0	240-474-8	*
Shellac	9000-59-3	232-549-9	*
Quinoline yellow E104	8004-92-0	Not listed	*

Additional Information: *** per tablet/capsule/lozenge/suppository

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance:CapsulesSignal Word:DANGER

Statement of Hazard: Toxic if swallowed.

May cause central nervous system effects

Additional Hazard Information:

Known Clinical Effects: Clinical use of this drug has caused sleepiness (somnolence), nausea, vomiting, dizziness.

Cases of severe overdose may lead to respiratory depression, mental confusion, coma,

seizure.

EU Indication of danger: Toxic

EU Hazard Symbols:

Material Name: Dextropropoxyphene Hydrochloride Capsules Page 2 of 6
Revision date: 15-Dec-2006 Version: 1.1

100101011 date: 10 200 2000



EU Risk Phrases:

R25 - Toxic if swallowed.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Eye Contact: Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical

attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes, skin, and clothing. Avoid generating airborne dust.

Material Name: Dextropropoxyphene Hydrochloride Capsules

Revision date: 15-Dec-2006 Version: 1.1

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

ACGIH Threshold Limit Value (TWA)

Corn Starch

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= 5 mg/m³ TWA = 10 mg/m³ TWA = 10 mg/m³ TWA

Talc (non-asbestiform)

Australia TWA

OSHA - Final PELs - Table Z-3 Mineral D: = 20 mppcf TWA
ACGIH Threshold Limit Value (TWA) = 2 mg/m³ TWA

Australia TWA = 2.5 mg/m³ TWA containing no asbestos fibers

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

Page 3 of 6

exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Capsule Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Povidone

Rat Oral LD50 100 g/kg

Page 4 of 6

Material Name: Dextropropoxyphene Hydrochloride Capsules

Revision date: 15-Dec-2006 Version: 1.1

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

FD & C Red No. 3 (E 127)

Rat Oral LD50 1840 mg/kg Mouse Oral LD50 1264 mg/kg

Dextropropoxyphene Hydrochloride

Rat Oral LD50 84 mg/kg Mouse Oral LD50 225 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Povidone

IARC: Group 3

Talc (non-asbestiform)

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

The following refers to all categories of classifications unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

Proper shipping name: Medicine, solid, toxic, n.o.s

Technical Shipping Name: Dextropropoxyphene Hydrochloride

UN / ID No:
Hazard class:
Calculate the state of the stat

DOT

DOT Proper shipping name: Consumer Commodity

DOT Hazard Class: ORM-D

Material Name: Dextropropoxyphene Hydrochloride Capsules

Revision date: 15-Dec-2006 Version: 1.1

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic

EU Risk Phrases:

R25 - Toxic if swallowed.

EU Safety Phrases:

S28 - After contact with skin, wash immediately with plenty of water.

S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label

Page 5 of 6

where possible).

OSHA Label:

DANGER

Toxic if swallowed.

May cause central nervous system effects

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 1, Subdivision B



Dextropropoxyphene Hydrochloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS List

216-683-5

Corn Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Povidone

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Gelatin

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-554-6

Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
238-877-9

FD & C Red No. 3 (E 127)

Page 6 of 6

Material Name: Dextropropoxyphene Hydrochloride Capsules

Revision date: 15-Dec-2006 Version: 1.1

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
240-474-8

Shellac

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-549-9

Quinoline yellow E104

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

16. OTHER INFORMATION

Reasons for Revision: Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology

Information. Updated Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet